Animal Model Market

Global Animal Model Market Size

The size of the global animal model market was valued at USD 2.25 billion in 2025. This market is expected to grow at a CAGR of 6.12% from 2026 to 2034 and be worth USD 3.84 billion by 2034 from USD 2.39 billion in 2026.

Animal models play a critical role in biomedical research which is serving as experimental tools to understand human diseases, test drug efficacy, and evaluate new therapeutic interventions. These models involve the use of various species such as mice, rats, zebrafish, primates, and others to simulate human physiological and pathological conditions. Moreover, the animal model market encompasses the development, breeding, supply, and utilization of these organisms across pharmaceutical, academic, and biotechnology sectors.

Like, as per the Foundation for Biomedical Research, rodent models alone account for more than 95% of all animals used in scientific investigations due to their genetic similarity with humans and ease of manipulation.

The demand for genetically modified animal models has surged, particularly in oncology, neurology, and immunology research. According to indication of a report by the European Commission, nearly 12 million procedures involving animals were conducted in EU member states in 2022, primarily for medical and veterinary research purposes.

With advancements in gene-editing technologies like CRISPR-Cas9, the precision and relevance of animal models have improved significantly, further strengthening their position in modern drug discovery and disease modeling frameworks.

MARKET DRIVERS

Expansion of Biopharmaceutical R&D Investments

A major driver of the Animal Model Market is the substantial growth in global biopharmaceutical research and development (R&D) expenditures. As pharmaceutical and biotech companies intensify their efforts to develop novel therapeutics, vaccines, and targeted treatments, the reliance on animal models for preclinical testing remains indispensable.

The investment surge is particularly evident in oncology, autoimmune disorders, and rare diseases, where animal models are essential for understanding disease mechanisms and evaluating drug responses before human trials.

Furthermore, in the United States, according to the National Cancer Institute, the majority of cancer drug development pipelines incorporate murine models to assess tumor response and toxicity profiles.

Besides, emerging markets such as China and India are expanding their domestic R&D capabilities. This sustained investment in life sciences R&D underscores the pivotal role of animal models in advancing medical innovation globally.

Advancements in Genetic Engineering Technologies

The rapid evolution of genetic engineering techniques, especially CRISPR-Cas9 and transgenic model development, has significantly propelled the Animal Model Market. These innovations allow researchers to create highly specific, humanized animal models that better mimic genetic diseases, immune responses, and metabolic conditions.

As per the journal Nature Biotechnology, CRISPR-based gene editing applications in animal models have grown by over 40% annually since 2018, enabling faster and more accurate disease modeling. Institutions like the Jackson Laboratory have reported a 60% increase in demand for genetically engineered mouse models (GEMMs) over the last five years, driven by their utility in personalized medicine and target validation.

In addition, as per the International Society for Transgenic Technologies, more than 500 new genetically modified animal strains are developed annually for use in preclinical research including models for Alzheimer’s, diabetes, and cardiovascular diseases.

Moreover, according to a study published by the Wellcome Sanger Institute, the cost of generating genetically modified models has dropped by nearly 50% since 2015 which is making them more accessible to academic and commercial research labs. This accessibility when combined with higher predictive accuracy enhances the translational value of animal models in drug development.

So, with ongoing improvements in gene-editing efficiency and regulatory support for advanced model creation, the adoption of genetically engineered animal models continues to expand, driving significant market growth.

MARKET RESTRAINTS

Ethical and Regulatory Concerns Surrounding Animal Testing

One of the most pressing restraints affecting the Animal Model Market is the increasing scrutiny surrounding ethical considerations and regulatory restrictions on animal experimentation. Public awareness and advocacy against animal testing have led to stricter legislation and greater emphasis on alternative methods such as in vitro models, organ-on-a-chip systems, and computational simulations.

According to the European Union Reference Laboratory for alternatives to animal testing (EURL ECVAM), over 30% of new drug candidates now undergo preliminary screening via non-animal models, reducing reliance on traditional animal testing.

In the United States, the National Institutes of Health (NIH) has introduced updated guidelines encouraging researchers to justify the necessity of animal models and explore alternative approaches wherever feasible. Also, as per a report by the Humane Society International, nearly 20 countries have implemented or proposed bans on cosmetic product testing involving animals, signaling a broader shift toward minimizing animal use in experimental settings.

These evolving ethical standards and regulatory pressures present a significant challenge to the continued expansion of the Animal Model Market.

High Costs and Complexity of Developing Specialized Models

Another major restraint in the Animal Model Market is the high cost and technical complexity associated with developing specialized, genetically engineered animal models. While these models offer superior accuracy in mimicking human diseases, their creation requires sophisticated infrastructure, skilled personnel, and extended timelines, making them financially prohibitive for many smaller research entities. For academic institutions and startups with limited funding, this presents a significant barrier to entry.

Moreover, as per the International Society for Transgenic Technologies, the average timeline for developing a validated transgenic model exceeds 12 months, including breeding, genotyping, and phenotypic characterization. This lengthy process delays research outcomes and increases operational costs.

Apart from these, maintaining high-standard vivarium facilities compliant with regulatory bodies such as AAALAC (Association for Assessment and Accreditation of Laboratory Animal Care) incurs recurring expenses.

These financial and logistical challenges limit the widespread adoption of advanced animal models, particularly among resource-constrained organizations, thereby restraining market growth despite strong scientific demand.

MARKET OPPORTUNITIES

Rising Demand for Personalized Medicine and Targeted Therapies

The growing emphasis on personalized medicine and targeted therapies presents a significant opportunity for the Animal Model Market. As healthcare shifts toward individualized treatment strategies based on genetic, environmental, and lifestyle factors, the need for precise preclinical models that reflect patient-specific pathologies has intensified.

According to the Personalized Medicine Coalition, over 40 new FDA-approved personalized medicines were launched between 2020 and 2023, each requiring tailored animal models for preclinical validation. These models help researchers assess drug interactions, biomarker responses, and potential side effects in a controlled setting before progressing to clinical trials.

Institutions like the Broad Institute and Memorial Sloan Kettering Cancer Center are increasingly utilizing patient-derived xenograft (PDX) models and humanized mice to replicate individual tumor biology and optimize therapy selection. According to a report by the Journal of Experimental & Clinical Cancer Research, PDX models have demonstrated over 80% concordance with original patient tumors, reinforcing their value in personalized oncology.

Increased Government Funding and Academic Research Initiatives

Government-backed funding programs and academic research initiatives represent a key opportunity for the Animal Model Market. Many national science foundations and health agencies are allocating significant resources to support preclinical research, particularly in areas such as neurodegenerative diseases, infectious diseases, and regenerative medicine.

According to the U.S. National Institutes of Health (NIH), total funding for biomedical research exceeded USD 47 billion in fiscal year 2023, with a considerable portion directed toward animal model-based studies. Programs like the NIH BRAIN Initiative and All of Us Research Program heavily rely on animal models to advance neurological and genomic research.

These sustained public investments provide a stable foundation for market expansion, ensuring continued reliance on animal models in cutting-edge scientific discoveries.

MARKET CHALLENGES

Technical Limitations in Disease Representation Across Species

A significant challenge facing the Animal Model Market is the inherent difficulty in accurately replicating human disease pathology in non-human species. Despite advances in genetic engineering, fundamental biological differences between animals and humans often lead to discrepancies in disease progression, immune response, and drug metabolism, limiting the translational reliability of preclinical findings.

According to a meta-analysis published in Science Translational Medicine, over 90% of drugs that show promise in animal trials fail during human clinical testing, largely due to poor predictability of animal models for human outcomes. This issue is particularly pronounced in fields such as neuroscience and immunology, where human-specific mechanisms play a dominant role.

Moreover, as per the Allen Institute for Brain Science, rodent models only partially replicate human brain structure and function , posing challenges in neurodegenerative disease research like Alzheimer’s and Parkinson’s.

Besides, as per the Journal of Autoimmunity, autoimmune disease models in mice frequently fail to capture the full spectrum of human immune responses, leading to inefficiencies in drug development pipelines.

These limitations show the urgent need for improved modeling techniques, including humanized models and interspecies comparisons, to enhance the predictive value of animal studies and reduce translational failures.

Shortage of Skilled Personnel and Standardization Issues

The Animal Model Market also faces challenges related to a shortage of trained professionals and inconsistencies in model standardization. Effective development and utilization of animal models require expertise in genetics, physiology, pathology, and regulatory compliance areas where there is a growing skills gap.

According to the National Institutes of Health (NIH), only 60% of research institutions have adequately trained personnel for advanced transgenic model development, leading to delays and inefficiencies in preclinical research. Furthermore, training programs for laboratory animal scientists have not kept pace with technological advancements, exacerbating workforce shortages.

Apart from these, as per the International Council for Laboratory Animal Science (ICLAS), there is a lack of globally harmonized protocols for model validation and reproducibility, resulting in variability in experimental outcomes across institutions and regions.

Moreover, according to a report by the National Academies of Sciences, reproducibility issues in preclinical research affect up to 50% of published animal studies, partly due to inconsistent handling, housing conditions, and genetic drift in animal colonies.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Animal Type Insights

The Mice segment dominated the Animal Model Market, accounting for 65.5% of total market share in 2024. This overwhelming dominance is attributed to their genetic similarity with humans, short reproductive cycles, and well-established transgenic modification techniques that make them ideal for biomedical research.

Their small size facilitates cost-effective housing and breeding at scale, making them a preferred choice across academic and industrial research settings.

Additionally, the widespread adoption of genetically engineered mouse models (GEMMs) has further enhanced their translational relevance, especially in personalized medicine and cancer research.

Institutions like the Broad Institute and Memorial Sloan Kettering Cancer Center heavily rely on murine models to simulate human tumor biology, reinforcing their central role in advancing precision therapies and expanding the global Animal Model Market.

Fish, particularly zebrafish, represent the fastest-growing segment in the Animal Model Market, projected to expand at a CAGR exceeding 9% from 2025 to 2033. This rapid growth is driven by increasing utilization of zebrafish in developmental biology, neurogenetics, and high-throughput drug screening due to their unique biological attributes.

According to the journal Development, zebrafish embryos develop externally and are transparent, enabling real-time visualization of organogenesis and disease progression. As per the Zebrafish Model Organism Database (ZFIN), over 40% of human disease-related genes have functional homologs in zebrafish, making them valuable for modeling genetic disorders such as muscular dystrophy and congenital heart defects.

Moreover, as per the European Molecular Biology Laboratory (EMBL), zebrafish-based drug discovery assays can screen up to 10,000 compounds per day, significantly accelerating pharmaceutical research timelines. Their ability to produce large numbers of offspring and short life cycle further enhances their appeal in large-scale genomic studies.

Academic institutions and biotech firms in North America and Europe are increasingly adopting zebrafish models for toxicity testing and regenerative medicine research, contributing to this segment’s accelerated growth trajectory within the Animal Model Market.

By Application Insights

Research and Development (R&D) spearheaded the application segment in the Animal Model Market, capturing 58.1% of total market revenue in 2024. This position is primarily driven by the indispensable role of animal models in preclinical trials, target validation, and mechanistic studies across the pharmaceutical and biotechnology sectors.

These models serve as critical tools for assessing drug efficacy, toxicity, and pharmacokinetics before progressing to human clinical trials.

Furthermore, as per the National Institutes of Health (NIH), a large share of new drugs entering clinical trials undergo prior testing in animal models, underscoring their regulatory importance. In areas such as oncology and rare diseases, animal models are essential for understanding complex pathophysiology and developing targeted interventions.

Additionally, this sustained demand reinforces the centrality of R&D applications in driving the overall Animal Model Market.

The Academics and Others segment is rising as the booming application area in the Animal Model Market, predicted to grow at a CAGR of approximately 8.7% through 2033. This surge is fueled by rising investments in academic research, government funding, and growing emphasis on basic science discoveries.

Universities and research centers are leveraging these models to explore neurological disorders, gene function, and developmental biology.

Moreover, UK universities alone conducted over 2 million procedures involving animals in 2022, primarily for fundamental research rather than applied drug testing. The expansion of collaborative research networks and open-access model repositories has further facilitated access to standardized animal models among academic researchers.

These factors collectively drive the rapid growth of this application segment.

By End-User Insights

Pharmaceutical companies grabbed the biggest end-user segment in the Animal Model Market, representing 42.6% of total market revenue in 2024. This lead position is due to the industry's heavy reliance on animal models for preclinical drug development, safety assessments, and regulatory submissions.

Regulatory agencies such as the FDA and EMA mandate animal studies before approving new therapeutics, ensuring continued demand for validated animal models across drug pipelines.

Additionally, as per the Personalized Medicine Coalition, oncology-focused drug development has surged by 30% since 2020, with many programs relying on genetically engineered mouse models (GEMMs) to evaluate novel immunotherapies. Biopharma giants like Roche, Merck, and AstraZeneca continue to invest in internal vivarium facilities or partner with contract research organizations (CROs) for scalable model access.

This strong integration into pharmaceutical workflows solidifies the dominance of this end-user segment in the Animal Model Market.

Contract Research Organizations (CROs) are emerging as the fastest-growing end-user segment in the Animal Model Market, projected to expand at a CAGR of around 9.2%. This growth is primarily driven by the increasing outsourcing of preclinical research by pharmaceutical and biotech firms seeking cost-effective, specialized services.

This trend is particularly evident in the United States and Europe, where CROs offer integrated solutions spanning study design, execution, and reporting.

Moreover, CROs like Charles River Laboratories, Envigo, and Covance have expanded their capabilities in genetically modified models, enhancing their value proposition for drug developers.

These factors collectively propel the rapid expansion of the CRO segment in the Animal Model Market.

REGIONAL ANALYSIS

North America Animal Model Market Insights

North America held the largest regional share of the Animal Model Market at 37.7% in 2024, driven by a robust biopharma ecosystem and strong government support for biomedical research. The United States, in particular, serves as a global hub for advanced drug development, with a dense network of pharmaceutical companies, academic research institutions, and CROs relying extensively on animal models.

Regulatory mandates also reinforce the demand for animal models, as the FDA requires extensive preclinical testing before approving new drugs. Moreover, leading CROs such as Charles River Laboratories and Envigo are headquartered in the U.S., offering comprehensive in vivo testing services to domestic and international clients.

With ongoing advancements in CRISPR technology and personalized medicine, North America remains at the forefront of innovation and adoption in the Animal Model Market.

Europe Animal Model Market Insights

Europe is a significant player in the global Animal Model Market, supported by its well-established research infrastructure and commitment to ethical oversight in animal experimentation. Countries such as the UK, Germany, France, and Sweden lead the region’s demand, backed by strong government-funded research initiatives and regulatory frameworks promoting responsible animal model use.

The implementation of Directive 2010/63/EU ensures high welfare standards while allowing controlled use of animal models in preclinical studies.

Moreover, academic institutions like the University of Cambridge and Karolinska Institute are actively engaged in refining model systems to improve translational accuracy.

Additionally, as per the European Molecular Biology Laboratory (EMBL), zebrafish and rodent models are widely used in neurogenetic and developmental studies, reflecting Europe’s strategic focus on cutting-edge biomedical applications. These factors collectively sustain Europe’s prominent position in the global Animal Model Market.

Asia-Pacific Animal Model Market Insights

Asia-Pacific is rapidly expanding in the global Animal Model Market, with China and India spearheading growth due to increasing investments in life sciences and expanding pharmaceutical R&D capabilities. The region is witnessing a surge in demand for standardized animal models driven by government-led initiatives and the rise of domestic biotech firms.

Institutions like the Chinese Academy of Sciences are investing in state-of-the-art vivarium facilities and genetically modified model repositories to support drug discovery efforts.

In India, as per the Department of Biotechnology (DBT), animal model research has grown by 15% annually over the past five years, aided by collaborations with international research bodies and the establishment of dedicated animal model resource centers.

Also, with improving regulatory frameworks and greater acceptance of animal-based research, Asia-Pacific is emerging as a key growth engine in the Animal Model Market.

Latin America Animal Model Market Insights

Latin America is still in an early phase of development compared to North America and Europe, the region is gradually strengthening its research infrastructure and expanding its engagement with preclinical studies.

The country’s growing biotech sector and expanding pharmaceutical manufacturing base are creating new opportunities for in vivo testing applications. Academic institutions in São Paulo and Mexico City are increasingly partnering with international organizations to access standardized animal models and enhance research quality.

While regulatory frameworks are evolving, there is a growing emphasis on ethical research practices and training programs for laboratory animal scientists. These developments indicate a positive trajectory for Latin America’s participation in the global Animal Model Market.

Middle East and Africa Animal Model Market Insights

The Middle East and Africa lags behind in terms of volume compared to other markets, it is showing gradual progress in research infrastructure and investment in life sciences.

In the UAE, Vision 2030 includes strategic goals for healthcare innovation and biotechnology development, prompting increased funding for medical research.

South Africa, being the most developed scientific hub in the region, is expanding its capacity for preclinical research. While challenges remain, the MEA region presents untapped potential for future expansion in the Animal Model Market.

COMPETITION OVERVIEW

The competition in the Animal Model Market is characterized by a mix of established players, emerging biotech firms, and academic institutions vying to meet the growing demand for high-quality, disease-specific models. Major corporations dominate due to their extensive model repositories, advanced breeding facilities, and strong distribution networks. However, increasing specialization in niche therapeutic areas is enabling smaller firms to carve out distinct market positions. Innovation remains a central battleground, with companies investing heavily in gene-editing technologies, cryopreservation methods, and digital pathology tools to enhance model accuracy and utility. Strategic collaborations are becoming more common, as firms seek to integrate complementary expertise and expand into new geographic regions. Additionally, the rise of contract research organizations offering bundled in vivo services is reshaping how pharmaceutical and biotech clients engage with the market. Ethical considerations and regulatory scrutiny are also influencing competitive dynamics, prompting players to emphasize responsible sourcing, transparency, and alternative modeling approaches.

KEY MARKET PLAYERS

Some of the companies that are playing a dominating role in the global animal model market include

• Horizon Discovery Group plc
• Trans Genic Inc.
• The Jackson Laboratory
• Genoway SA
• Transposagen Biopharmaceuticals, Inc.
• Crown Bioscience, Inc.
• Envigo CRS SA
• Eurofins Scientific SE
• Charles River Laboratories International, Inc.
• Taconic Biosciences, Inc.

TOP LEADING PLAYERS IN THE MARKET

Charles River Laboratories is a global leader in the discovery and development of animal models for preclinical research. The company provides a comprehensive portfolio of rodent models, genetically engineered strains, and customized breeding services to pharmaceutical and biotech firms. By offering integrated solutions that span model generation, housing, and experimental execution, Charles River plays a pivotal role in accelerating drug development pipelines. Their commitment to innovation, quality assurance, and ethical standards has made them a trusted partner across the life sciences industry.

Envigo is a key player known for its extensive expertise in supplying high-quality research models and associated services. The company supports academic institutions, pharmaceutical companies, and CROs by providing specialized animal models tailored for specific therapeutic areas. Envigo’s focus on health monitoring, genetic integrity, and regulatory compliance ensures reliable data outcomes for clients. Its acquisition by a private equity firm in recent years has enabled greater investment in infrastructure and expansion of service offerings globally.

The Jackson Laboratory is a non-profit institution that plays a foundational role in advancing mammalian genetics and genomics through animal modeling. JAX develops and distributes genetically defined mouse models critical for biomedical research, particularly in oncology, neuroscience, and immunology. It also offers custom model creation, training programs, and bioinformatics resources. As a leader in translational research, JAX contributes significantly to scientific advancements and serves as a vital resource for researchers worldwide.

TOP STRATEGIES USED BY KEY MARKET PARTICIPANTS

One major strategy employed by leading players in the Animal Model Market is expanding capabilities in genetically engineered model development, allowing companies to offer highly specialized models that better mimic human diseases. This enables clients to conduct more predictive preclinical studies and improve translational outcomes.

An additional prevalent approach is strategic acquisitions and partnerships, where companies acquire smaller model development firms or collaborate with academic institutions to enhance their product portfolios and access novel technologies. These moves help consolidate market presence and accelerate innovation cycles.

Next key strategy involves investing in centralized vivarium infrastructure and outsourcing services, catering to pharmaceutical and biotech firms seeking cost-effective, end-to-end solutions.

GLOBAL ANIMAL MODEL MARKET NEWS

• In February 2023, Charles River Laboratories expanded its facility in Reno, Nevada, focusing on enhancing capacity for custom transgenic model development, reinforcing its leadership in genetically engineered animal models.
• In August 2023, Envigo launched a new line of immunodeficient rodent models designed specifically for oncology and immuno-oncology research, broadening its portfolio of specialized research tools for cancer therapies.
• In January 2024, The Jackson Laboratory introduced an online platform offering real-time genetic tracking and phenotyping data for its mouse models, improving accessibility and usability for academic and industrial researchers.
• In April 2024, Taconic Biosciences partnered with a leading CRISPR technology provider to co-develop next-generation humanized models, aiming to enhance translational relevance for drug discovery applications.
• In July 2024, InVivos Australia acquired a local biobanking startup to strengthen its capabilities in preserving and distributing rare and genetically modified animal lines, supporting long-term research sustainability.

MARKET SEGMENTATION

This research report on the global animal model market research report is segmented and sub-segmented into the following categories.

By Animal Type

• Mice
• Birds
• Fish
• Cattles

By Application:

• Research and Development
• Production and Quality Control
• Academics
• Others

By End-User

• Research Institutes
• Pharmaceutical Companies
• CRO (Contract Research Organizations)
• Educational Institutes

By Region

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East & Africa